Effect of non-Vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer

Kyu Kim, Yong Joon Lee, Tae Hoon Kim, Jae Sun Uhm, Hui Nam Pak, Moon Hyoung Lee, Boyoung Joung

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and Objectives: There are limited data on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fbrillation (AF) patients with cancer. We aimed to assess the efcacy and safety of NOACs in AF patients with cancer in this study. Methods: In 2,568 consecutive non-valvular AF patients with newly diagnosed cancer, we analyzed ischemic stroke/systemic embolism (SE), major bleeding, and all-cause death. Based on propensity score matching, 388 matched pairs were included in the NOAC and warfarin groups. Results: Patient baseline characteristics were comparable between the matched groups. During median follow-up of 1.8 years, the NOAC group had signifcantly lower incidences of ischemic stroke/SE (p<0.001), major bleeding (p<0.001), and all-cause death (p<0.001) than the warfarin group. Moreover, the incidence of major bleeding was signifcantly lower in the NOAC group than in the warfarin group with optimal international normalized ratio control (p=0.03). Especially, within 1 year afer cancer diagnosis, the incidences of all clinical events were signifcantly lower in the NOAC group than in the warfarin group. Conclusions: In AF patients with newly diagnosed cancer, NOACs showed lower incidences of ischemic stroke/SE, major bleeding, and all-cause death than warfarin, especially within 1 year afer cancer diagnosis.

Original languageEnglish
Pages (from-to)406-417
Number of pages12
JournalKorean Circulation Journal
Volume48
Issue number5
DOIs
Publication statusPublished - 2018 May

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Effect of non-Vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer'. Together they form a unique fingerprint.

  • Cite this